Which has better valuation & earnings, PLYX or BGM?

Polaryx Therapeutics has higher earnings, but lower revenue than BGM Group. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Polaryx Therapeutics N/A N/A N/A N/A N/A BGM Group $25.10M 1.32 -$1.44M N/A N/A

Is PLYX or BGM more profitable?

Company Net Margins Return on Equity Return on Assets Polaryx Therapeutics N/A N/A N/A BGM Group N/A N/A N/A

Do analysts recommend AIFC or BGM?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ALT5 Sigma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 BGM Group 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has higher valuation & earnings, AIFC or BGM?

BGM Group has higher revenue and earnings than ALT5 Sigma. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio ALT5 Sigma $24.84M 3.74 -$344.51M N/A N/A BGM Group $25.10M 1.32 -$1.44M N/A N/A

Is AIFC or BGM more profitable?

BGM Group has a net margin of 0.00% compared to ALT5 Sigma's net margin of -2,483.94%. BGM Group's return on equity of 0.00% beat ALT5 Sigma's return on equity. Company Net Margins Return on Equity Return on Assets ALT5 Sigma -2,483.94% -68.25% -62.43% BGM Group N/A N/A N/A

Do analysts recommend ENGN or BGM?

enGene presently has a consensus price target of $12.68, suggesting a potential upside of 675.65%. Given enGene's stronger consensus rating and higher probable upside, analysts clearly believe enGene is more favorable than BGM Group. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score enGene 1 Sell rating(s) 9 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.21 BGM Group 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has stronger earnings & valuation, ENGN or BGM?

BGM Group has higher revenue and earnings than enGene. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio enGene N/A N/A -$117.30M -$2.25 N/A BGM Group $25.10M 1.32 -$1.44M N/A N/A

Is ENGN or BGM more profitable?

BGM Group's return on equity of 0.00% beat enGene's return on equity. Company Net Margins Return on Equity Return on Assets enGene N/A -55.83% -45.74% BGM Group N/A N/A N/A

Do analysts rate BGM or LFVN?

Lifevantage has a consensus target price of $5.00, suggesting a potential downside of 49.93%. Given Lifevantage's stronger consensus rating and higher possible upside, analysts plainly believe Lifevantage is more favorable than BGM Group. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score BGM Group 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Lifevantage 0 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has higher earnings & valuation, BGM or LFVN?

Lifevantage has higher revenue and earnings than BGM Group. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio BGM Group $25.10M 1.32 -$1.44M N/A N/A Lifevantage $228.53M 0.55 $9.81M $0.45 22.19

Do analysts rate BGM or OTLK?

Oncobiologics has a consensus price target of $4.50, indicating a potential upside of 536.49%. Given Oncobiologics' stronger consensus rating and higher possible upside, analysts plainly believe Oncobiologics is more favorable than BGM Group. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score BGM Group 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Oncobiologics 1 Sell rating(s) 5 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has preferable earnings & valuation, BGM or OTLK?

BGM Group has higher revenue and earnings than Oncobiologics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio BGM Group $25.10M 1.32 -$1.44M N/A N/A Oncobiologics $1.35M 73.34 -$62.42M -$1.17 N/A

Is BGM or OTLK more profitable?

Company Net Margins Return on Equity Return on Assets BGM Group N/A N/A N/A Oncobiologics N/A N/A -291.28%

BGM Group (BGM) Competitors

$0.34 +0.02 (+6.91%)

As of 11:12 AM Eastern

Compare

BGM vs. PLYX, AIFC, ENGN, LFVN, and OTLK

Should you buy BGM Group stock or one of its competitors? MarketBeat compares BGM Group with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with BGM Group include Polaryx Therapeutics (PLYX), ALT5 Sigma (AIFC), enGene (ENGN), Lifevantage (LFVN), and Oncobiologics (OTLK). These companies are all part of the "pharmaceutical products" industry.

How does BGM Group compare to Polaryx Therapeutics?

Polaryx Therapeutics (NASDAQ:PLYX) and BGM Group (NASDAQ:BGM) are both small-cap pharmaceutical products companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, media sentiment, risk, institutional ownership, earnings, profitability, valuation and analyst recommendations.

Polaryx Therapeutics has higher earnings, but lower revenue than BGM Group.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Polaryx Therapeutics	N/A	N/A	N/A	N/A	N/A
BGM Group	$25.10M	1.32	-$1.44M	N/A	N/A

Company	Net Margins	Return on Equity	Return on Assets
Polaryx Therapeutics	N/A	N/A	N/A
BGM Group	N/A	N/A	N/A

Polaryx Therapeutics currently has a consensus target price of $10.00, indicating a potential upside of 328.27%. Given Polaryx Therapeutics' stronger consensus rating and higher possible upside, equities research analysts plainly believe Polaryx Therapeutics is more favorable than BGM Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Polaryx Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
BGM Group	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Polaryx Therapeutics' average media sentiment score of 0.00 equaled BGM Group'saverage media sentiment score.

Company	Overall Sentiment
Polaryx Therapeutics	Neutral
BGM Group	Neutral

Summary

Polaryx Therapeutics beats BGM Group on 3 of the 4 factors compared between the two stocks.

How does BGM Group compare to ALT5 Sigma?

ALT5 Sigma (NASDAQ:AIFC) and BGM Group (NASDAQ:BGM) are both small-cap pharmaceutical products companies, but which is the better business? We will compare the two businesses based on the strength of their profitability, valuation, institutional ownership, dividends, risk, media sentiment, analyst recommendations and earnings.

ALT5 Sigma has a beta of 1.71, indicating that its share price is 71% more volatile than the broader market. Comparatively, BGM Group has a beta of 1.81, indicating that its share price is 81% more volatile than the broader market.

In the previous week, ALT5 Sigma's average media sentiment score of 0.00 equaled BGM Group'saverage media sentiment score.

Company	Overall Sentiment
ALT5 Sigma	Neutral
BGM Group	Neutral

BGM Group has higher revenue and earnings than ALT5 Sigma.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ALT5 Sigma	$24.84M	3.74	-$344.51M	N/A	N/A
BGM Group	$25.10M	1.32	-$1.44M	N/A	N/A

BGM Group has a net margin of 0.00% compared to ALT5 Sigma's net margin of -2,483.94%. BGM Group's return on equity of 0.00% beat ALT5 Sigma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ALT5 Sigma	-2,483.94%	-68.25%	-62.43%
BGM Group	N/A	N/A	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ALT5 Sigma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
BGM Group	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

6.3% of ALT5 Sigma shares are held by institutional investors. 0.2% of ALT5 Sigma shares are held by insiders. Comparatively, 58.7% of BGM Group shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Summary

BGM Group beats ALT5 Sigma on 7 of the 9 factors compared between the two stocks.

How does BGM Group compare to enGene?

enGene (NASDAQ:ENGN) and BGM Group (NASDAQ:BGM) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, dividends, analyst recommendations, risk, valuation, profitability, institutional ownership and earnings.

64.2% of enGene shares are owned by institutional investors. 10.5% of enGene shares are owned by insiders. Comparatively, 58.7% of BGM Group shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

BGM Group's return on equity of 0.00% beat enGene's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
enGene	N/A	-55.83%	-45.74%
BGM Group	N/A	N/A	N/A

BGM Group has higher revenue and earnings than enGene.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
enGene	N/A	N/A	-$117.30M	-$2.25	N/A
BGM Group	$25.10M	1.32	-$1.44M	N/A	N/A

enGene has a beta of -0.29, indicating that its stock price is 129% less volatile than the broader market. Comparatively, BGM Group has a beta of 1.81, indicating that its stock price is 81% more volatile than the broader market.

In the previous week, enGene had 13 more articles in the media than BGM Group. MarketBeat recorded 13 mentions for enGene and 0 mentions for BGM Group. BGM Group's average media sentiment score of 0.00 beat enGene's score of -0.06 indicating that BGM Group is being referred to more favorably in the news media.

Company	Overall Sentiment
enGene	Neutral
BGM Group	Neutral

enGene presently has a consensus price target of $12.68, suggesting a potential upside of 675.65%. Given enGene's stronger consensus rating and higher probable upside, analysts clearly believe enGene is more favorable than BGM Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
enGene	1 Sell rating(s)	9 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.21
BGM Group	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

BGM Group beats enGene on 7 of the 12 factors compared between the two stocks.

How does BGM Group compare to Lifevantage?

BGM Group (NASDAQ:BGM) and Lifevantage (NASDAQ:LFVN) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, dividends, profitability, earnings, analyst recommendations, risk, institutional ownership and media sentiment.

In the previous week, Lifevantage had 2 more articles in the media than BGM Group. MarketBeat recorded 2 mentions for Lifevantage and 0 mentions for BGM Group. Lifevantage's average media sentiment score of 0.34 beat BGM Group's score of 0.00 indicating that Lifevantage is being referred to more favorably in the news media.

Company	Overall Sentiment
BGM Group	Neutral
Lifevantage	Neutral

Lifevantage has a consensus target price of $5.00, suggesting a potential downside of 49.93%. Given Lifevantage's stronger consensus rating and higher possible upside, analysts plainly believe Lifevantage is more favorable than BGM Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BGM Group	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Lifevantage	0 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

BGM Group has a beta of 1.81, meaning that its stock price is 81% more volatile than the broader market. Comparatively, Lifevantage has a beta of 0.68, meaning that its stock price is 32% less volatile than the broader market.

Lifevantage has a net margin of 2.94% compared to BGM Group's net margin of 0.00%. Lifevantage's return on equity of 23.89% beat BGM Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BGM Group	N/A	N/A	N/A
Lifevantage	2.94%	23.89%	12.47%

35.3% of Lifevantage shares are held by institutional investors. 58.7% of BGM Group shares are held by company insiders. Comparatively, 22.0% of Lifevantage shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Lifevantage has higher revenue and earnings than BGM Group.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BGM Group	$25.10M	1.32	-$1.44M	N/A	N/A
Lifevantage	$228.53M	0.55	$9.81M	$0.45	22.19

Summary

Lifevantage beats BGM Group on 10 of the 13 factors compared between the two stocks.

How does BGM Group compare to Oncobiologics?

BGM Group (NASDAQ:BGM) and Oncobiologics (NASDAQ:OTLK) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, valuation, profitability, earnings, institutional ownership, analyst recommendations, risk and media sentiment.

Oncobiologics has a consensus price target of $4.50, indicating a potential upside of 536.49%. Given Oncobiologics' stronger consensus rating and higher possible upside, analysts plainly believe Oncobiologics is more favorable than BGM Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BGM Group	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Oncobiologics	1 Sell rating(s)	5 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

BGM Group has a beta of 1.81, suggesting that its share price is 81% more volatile than the broader market. Comparatively, Oncobiologics has a beta of 0.94, suggesting that its share price is 6% less volatile than the broader market.

11.2% of Oncobiologics shares are owned by institutional investors. 58.7% of BGM Group shares are owned by company insiders. Comparatively, 1.8% of Oncobiologics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

In the previous week, Oncobiologics had 5 more articles in the media than BGM Group. MarketBeat recorded 5 mentions for Oncobiologics and 0 mentions for BGM Group. Oncobiologics' average media sentiment score of 1.02 beat BGM Group's score of 0.00 indicating that Oncobiologics is being referred to more favorably in the news media.

Company	Overall Sentiment
BGM Group	Neutral
Oncobiologics	Positive

Company	Net Margins	Return on Equity	Return on Assets
BGM Group	N/A	N/A	N/A
Oncobiologics	N/A	N/A	-291.28%

BGM Group has higher revenue and earnings than Oncobiologics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BGM Group	$25.10M	1.32	-$1.44M	N/A	N/A
Oncobiologics	$1.35M	73.34	-$62.42M	-$1.17	N/A

Summary

Oncobiologics beats BGM Group on 7 of the 12 factors compared between the two stocks.

Get BGM Group News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BGM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BGM vs. The Competition

Export

Metric	BGM Group	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$33.25M	$3.31B	$6.46B	$11.95B
Dividend Yield	N/A	2.31%	2.67%	5.58%
P/E Ratio	N/A	19.05	23.94	23.78
Price / Sales	1.32	305.18	531.66	117.30
Price / Cash	N/A	51.45	26.99	37.25
Price / Book	0.05	8.09	10.55	6.76
Net Income	-$1.44M	$23.89M	$3.56B	$337.14M
7 Day Performance	5.23%	-3.06%	-0.93%	-1.75%
1 Month Performance	16.72%	2.84%	1.58%	2.32%
1 Year Performance	-97.41%	36.43%	20.99%	25.63%

BGM Group Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BGM BGM Group	0.908 of 5 stars	$0.34 +6.9%	N/A	-97.6%	$33.25M	$25.10M	N/A	298
PLYX Polaryx Therapeutics	4.1153 of 5 stars	$2.64 -5.7%	$10.00 +278.8%	N/A	$124.16M	N/A	N/A	11	Positive News Gap Up
AIFC ALT5 Sigma	0.1089 of 5 stars	$0.79 -8.3%	N/A	-93.6%	$120.26M	$24.84M	N/A	170
ENGN enGene	4.1147 of 5 stars	$1.74 -2.2%	$12.68 +628.8%	-56.3%	$119.23M	N/A	N/A	31	Upcoming Earnings
LFVN Lifevantage	2.4377 of 5 stars	$8.62 -8.6%	$5.00 -42.0%	-14.5%	$118.97M	$228.53M	19.16	260	High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:BGM) was last updated on 6/9/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

BGM Group (BGM) Competitors

BGM vs. PLYX, AIFC, ENGN, LFVN, and OTLK

How does BGM Group compare to Polaryx Therapeutics?

Summary

How does BGM Group compare to ALT5 Sigma?

Summary

How does BGM Group compare to enGene?

Summary

How does BGM Group compare to Lifevantage?

Summary

How does BGM Group compare to Oncobiologics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BGM vs. The Competition

BGM Group Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

BGM Group (BGM) Competitors

BGM vs. PLYX, AIFC, ENGN, LFVN, and OTLK

How does BGM Group compare to Polaryx Therapeutics?

Which has better valuation & earnings, PLYX or BGM?

Is PLYX or BGM more profitable?

Do analysts prefer PLYX or BGM?

Does the media favor PLYX or BGM?

Summary

How does BGM Group compare to ALT5 Sigma?

Which has more volatility and risk, AIFC or BGM?

Does the media refer more to AIFC or BGM?

Which has higher valuation & earnings, AIFC or BGM?

Is AIFC or BGM more profitable?

Do analysts recommend AIFC or BGM?

Do institutionals & insiders believe in AIFC or BGM?

Summary

How does BGM Group compare to enGene?

Do institutionals and insiders hold more shares of ENGN or BGM?

Is ENGN or BGM more profitable?

Which has stronger earnings & valuation, ENGN or BGM?

Which has more volatility & risk, ENGN or BGM?

Does the media refer more to ENGN or BGM?

Do analysts recommend ENGN or BGM?

Summary

How does BGM Group compare to Lifevantage?

Does the media prefer BGM or LFVN?

Do analysts rate BGM or LFVN?

Which has more risk & volatility, BGM or LFVN?

Is BGM or LFVN more profitable?

Do institutionals & insiders hold more shares of BGM or LFVN?

Which has higher earnings & valuation, BGM or LFVN?

Summary

How does BGM Group compare to Oncobiologics?

Do analysts rate BGM or OTLK?

Which has more risk & volatility, BGM or OTLK?

Do institutionals & insiders believe in BGM or OTLK?

Does the media refer more to BGM or OTLK?

Is BGM or OTLK more profitable?

Which has preferable earnings & valuation, BGM or OTLK?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BGM vs. The Competition

BGM Group Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools